Human platelet activation by thrombolytic agents: Effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression - 09/09/11
Abstract |
The mechanisms that underlie reocclusion during thrombolytic therapy have not yet been clarified. The purpose of this study was to investigate the activating effects of tissue-type plasminogen activator and urokinase and the inhibitory effects of acetylsalicylic acid by measuring platelet surface P-selectin as a marker of platelet activation. After addition of urokinase (final concentration 192 U/ml, 1920 U/ml, or 19,200 U/ml) or tissue-type plasminogen activator (final concentration 120 U/ml, 1200 U/ml, or 12,000 U/ml) to platelet-rich plasma from 12 healthy persons, platelet surface P-selectin expression was measured by means of flow cytometry with an anti-CD62 monoclonal antibody. The presence of urokinase and tissue-type plasminogen activator increased platelet surface P-selectin expression in a concentration-dependent manner. In the next step, either 160 mg/day (n = 6) or 660 mg/day (n = 6) acetylsalicylic acid was administered to the 12 healthy persons, and venous blood samples were collected after 7 days of treatment. Platelet surface P-selectin expression was measured with the method used earlier and after addition of tissue-type plasminogen activator or urokinase. Although the effect of acetylsalicylic acid at 160 mg/day on P-selectin expression was minimal, a dose of 660 mg/day suppressed platelet P-selectin expression and inhibited the platelet activating effects of tissue-type plasminogen activator and urokinase in a statistically significant way. Platelets were activated by tissue-type plasminogen activator or urokinase, and this platelet activation was suppressed with administration of acetylsalicylic acid at 660 mg/day. (Am Heart J 1998;135:268-71.)
Le texte complet de cet article est disponible en PDF.Plan
 | From the Second Department of Internal Medicine, Kyorin University School of Medicine. |
| Supported in part by grant-in-aid no 08670823 for scientific research from the Ministry of Education, Tokyo, Japan. |
 | Reprint requests: Kyozo Ishikawa, MD, Second Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka-city, Tokyo 181, Japan. |
| 4/1/86116 |
Vol 135 - N° 2
P. 268-271 - février 1998 Retour au numéro
Article précédent
- Effects of propranolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression
- Kalyanam Shivkumar, Lonni Schultz, Sidney Goldstein, Mihai Gheorghiade
- Adding the new calcium antagonist mibefradil to patients receiving long-term β-blocker therapy results in improved antianginal and antiischemic efficacy
- Adam Schneeweiss, Isaac Kobrin, Vincent Charlon, Abraham Caspi, Alon Marmor, Samuel Sclarovsky, Leonardo Reisin, Zvi Zchlesinger
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?